

#### SHREE GANESH REMEDIES LIMITED

Mfg. Pharmaceutical Intermediates & Fine Chemicals

Date: August 21, 2020

To,
The Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001.
Scrip Code: 540737

Dear Sir(s)/Ma'am,

#### Sub: Outcome of Board Meeting

Pursuant to Regulations 30 and 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule III to the said Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on Friday, August 21, 2020 (which commenced at 03.30 p.m. and concluded at 04:30 p.m.), inter alia, have approved / noted the following:

#### (a) Increase in the Authorised Share Capital of the Company:-

Increase in Authorised Share Capital of the Company from existing Rs. 10,00,00,000/-(Rupees Ten Crore only) divided into 1,00,00,000 (One Crore Only) Equity Shares of Rs. 10/- (Rupees Ten Only) each to Rs. 15,00,00,000/- (Rupees Fifteen Crores Only) divided into 1,40,00,000 (One Crore Forty Lakhs) Equity Shares of Rs. 10/- (Rupees Ten Only) each and 10,00,000 (Ten Lakhs) Preference Shares of Rs. 10 (Rupees Ten Only) each.

#### (b) Issue of Bonus shares:-

Issue of bonus shares in the ratio of 3 (Three) equity shares for every 26 (Twenty-Six) existing equity shares held by the shareholders of the Company as on the record date to be determined for the said purpose.

The details pertaining to Issue of Bonus Shares as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in **Annexure - 1** attached herewith.

### (c) Migration of the Company from SME Platform of BSE Limited to Main Board of BSE Limited: -

The board has approved the Migration of the Company from SME Platform of BSE Limited to Main Board of BSE Limited.





**GANESH GROUP** 

Reg. Office:

Plot No. 6011-12, GIDC Estate, Ankleshwar - 393 002, Gujarat (INDIA) Ph.: +91 2646-227777, 7574976076 CIN No.: L2423GJ1995PTC025661

GSTIN: 24ABACS1471R1Z0



Plot No. 6714/2,-6715 GIDC Estate, Ankleshwar - 393 002, Gujarat (INDIA) (Formaly know as Ashok Pharma Chem)







www.ganeshremedies.com



# (d) Appointment of Mr. Gunjan Chandulal Kothia as Wholetime Director of the Company:-

The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee of the Board of Directors, have appointed Mr. Gunjan Chandulal Kothia as "Wholetime Director" (Executive, Promoter) with immediate effect, subject to approval of the shareholders of the Company. Details of the same are attached in **Annexure-2**.

#### (e) Induction of Mr. Parth Chandulal Kothia as "Additional Director":

The Board of Directors of the Company had kept the same in abeyance.

## (f) Approval of Notice of Annual General Meeting (AGM) & Fixation the Record date for Dividend and Book Closure for AGM:-

The Register of members and share transfer books of the Company shall remain closed from *Thursday, September 03, 2020 to Saturday, September 19, 2020*, and the record date for the purpose of dividend and determining eligibility of members for the purpose of voting at the 25th Annual General Meeting is **Wednesday, September 02, 2020**.

#### (g) Approval of the draft of the Postal Ballot Notice:-

The board has approved the notice of the Postal Ballot.

#### (h) Appointment of the Scrutinizer:-

The Board has appointed M/s. Vishal Thawani & Associates, Practising Company Secretaries, as Scrutinizer.

Submitted for your kind information and necessary records.

Thanking you,

Yours faithfully,

For, SHREE GANESH REMEDIES LIMITED

Chandulal Manubhai Kothia Managing Director

**DIN:** 00652806

# Annexure-1 Details pertaining to Issue of Bonus Shares as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sr. No.	Particulars	Description
1	Whether bonus is out of free reserves created out of profits or share premium account	Bonus Shares will be issued out of the Securities Premium Account, Profit and Loss Account, General Reserves or any combination thereof of the Company.
2	Bonus Ratio	(3:26) i.e. 3 (Three) fully paid-up equity shares for every 26 (Twenty Six) existing fully paid-up equity shares.
3	Details of share capital- pre and post bonus issue	The pre-bonus paid-up equity share capital as on the date of this letter is Rs. 8,97,13,560/- consisting of 89,71,356 equity shares of Rs. 10/- each.
		The post-bonus paid-up equity share capital is expected to be around Rs. 10,00,65,120/- consisting of 1,00,06,512 equity shares of Rs. 10/-each. The actual number of bonus equity shares to be issued will be determined based on the paid-up share capital as on the record date.
4	Free Reserves and/or share premium required	Amount required for Bonus Issue: <b>Rs. 1,03,51,565</b>
5	Free Reserves and/or share premium available for capitalization and the date as on which such balance is available;	Rs. 7,00,54,215 (Securities Premium Amount available as per latest audited Balance Sheet on March 31, 2020)
6	Whether the aforesaid figures are audited	Yes
7	Estimated date by which such bonus shares would be credited/dispatched	



#### Annexure- 2

Disclosure required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, with regard to change in Directors and Key Managerial Personnel is given herein under:-

Sr. No	Details of the events that needs to be provided	Information of such event(s)
1	Reason for Change viz. Appointment, Resignation, Removal, Death or otherwise;	Appointment of Mr. Gunjan Chandulal Kothia as an Wholetime Director (Executive, Promoter)
2	Date of Appointment / Cessation (as applicable) Term of Appointment	At the Board Meeting i.e. August 21, 2020.  Five years with effect from August 21, 2020 to hold office upto August 20,
		2025, subject to approval of the shareholders.
3	Brief Profile (In case of Appointment)	Mr. Gunjan Chandulal Kothia is an Graduate in Chemical Engineering and has done Master in Science, Leeds University, United Kingdom and has working experience of two years in Research & Development of Pharmaceutical Intermediates & three years in Business Development of Pharmaceutical Intermediates and Organic Pigments. Apart from this he has technical know-how of different organic chemical synthesis and application of Organic phthalocyanine Pigments. He is young and dynamic and very adaptable and updated to the changing legislations.
4	Disclosure of Relationships between directors (in case of appointment of a director)	Mr. Gunjan Chandulal Kothia is son of Mr. Chandulal Manubhai Kothia, Managing Director of the Company and Mr. Hasmukhbhai Kothia is his Uncle.
5	Names of Listed entities in which the person also holds the directorship and the membership of Committees of the Board.	Nil
6	Shareholding in the Company	Nil

